This suggests that chiglitazar alleviates sepsis-induced NAD+ depletion not by merely compensating for SIRT1 substrate demand in the cytoplasm but through metabolic reprogramming that redirects NAD+ toward sustaining mitochondrial respiration and redox homeostasis. This evidence concerns the gene SIRT1 and Sepsis.